Do Red Light and Near-Infrared Work on Different Cells or Tissues?

Created on July 24, 2026 Written by Evelyn Reed, M.S.

Not in a simple cell-type split. Red and near-infrared (NIR) light are not established as separate treatments for separate categories of cells. They are thought to share some proposed cellular mechanisms. The more practical difference is how each wavelength is absorbed and scattered as it passes through tissue, which can change the amount of light likely to reach a superficial or deeper target.

That distinction matters, but it is only a starting point. A wavelength label does not establish that a device delivers a useful dose to a particular tissue---or that it improves a health outcome. Device output, treatment time, distance, treatment area, anatomy, and condition-specific human evidence all matter.

Red and NIR are not separate "cell-type" treatments

Photobiomodulation research generally concerns red-to-near-infrared light, with wavelengths from roughly 600 to 1,100 nm discussed in the literature. Studies have commonly used wavelengths in the 630--810 nm range, including 670 nm and 808 nm. Those are reported research ranges, not universal prescriptions for every target or condition.

A leading proposed mechanism is interaction with mitochondrial cytochrome oxidase. Proposed downstream changes include electron transport, ATP production, calcium signaling, and antioxidant pathways. However, these mechanisms are not fully settled, and much of the underlying evidence comes from cell and animal research rather than definitive studies showing a clinical effect in every human tissue. Read the photobiomodulation mechanisms review.

So it is not accurate to say:

• red light works only on skin cells;
• NIR works only on muscle, joints, or nerves; or
• either wavelength automatically works wherever it can physically travel.

Cells in different tissues may receive different amounts of light because of the tissue between the device and the intended target. That light-delivery question is usually more useful than a "which cells does it work on?" question.

Wavelength changes light delivery, not the evidence standard

Red and NIR light encounter tissue differently. In general, NIR has an optical rationale for reaching beyond the surface in some settings because it may be absorbed less strongly by some major tissue chromophores than shorter visible wavelengths.

But "penetration" is not a fixed number. Penetration can vary with individual anatomy, pigmentation, tissue composition, and device setup.

Even reported penetration differs substantially across species. At 850 nm, one reviewed source described penetration in humans as approximately three times greater than in mice. That is a useful reminder not to translate laboratory or animal depth claims directly to a person, a particular joint, or a home device setup.

The practical distinction is therefore modest but important:

• For a surface-facing target, such as skin, red light may be a reasonable wavelength to investigate.
• For a target beneath the surface, NIR may be more relevant to investigate because it has greater potential to travel beyond superficial tissue in some circumstances.
• For either target, optical plausibility is not proof of benefit.

A device may emit NIR without delivering a clinically meaningful dose to the tissue you care about. Likewise, a red-plus-NIR device is not automatically more appropriate than a device using one wavelength range.

Choose the target first, then look for human evidence

It helps to separate two questions that are often combined in marketing:

1. Could light plausibly reach this general depth?
2. Has a specific device approach shown a meaningful human outcome for this condition?

The first is an optics question. The second requires controlled human research.

Intended target	What wavelength can tell you	What it cannot tell you
Skin or other superficial areas	Red light may be a direct wavelength range to investigate for a surface target.	It does not establish a skin-specific outcome, appropriate dose, or suitability for an individual concern.
Muscle, tendons, joints, or nerves	NIR may have greater potential to reach beyond the surface than red in some settings.	It does not establish that a useful dose reaches a specific tendon, joint, or nerve, or that the light improves a diagnosed condition.
Brain, bone, internal organs, or a named deep joint	A deeper target is a reason to demand better evidence, not to assume NIR reaches it effectively.	A consumer-device penetration claim alone does not demonstrate target dose or clinical benefit.

Tendinopathy illustrates why depth is not enough. A systematic review summarized 17 randomized trials involving 835 participants and found no significant pain difference when photobiomodulation alone was compared with other interventions. The evidence for that comparison was rated very low quality, and diagnoses and treatment parameters varied substantially.

Photobiomodulation combined with exercise reduced pain more than sham plus exercise in the review summary, but that evidence was low quality. It also did not differ from other interventions combined with exercise. Exercise remained the mainstay treatment in the review's interpretation.

This does not prove that light has no role in every tendon problem. It does show why "NIR reaches deeper" is not a substitute for evidence on the exact condition, outcome, protocol, and comparison that matter to you. In many of the reviewed trials, critical details such as wavelength, power output, or fluence per spot were incompletely reported, making it difficult to attribute outcomes to wavelength, penetration, or dose.

Dose is more than a wavelength number

Two devices can list the same wavelength yet deliver very different treatment conditions. Published photobiomodulation outcomes may be affected by:

• irradiance, sometimes called power density;
• exposure time;
• energy delivered over the treatment area;
• treatment area and coverage;
• device distance and whether the device is used in contact with the body;
• pulse settings and fractionation, where relevant.

Research settings have varied widely. Reported studies included power densities from 7.5 to 250 mW/cm² and energy densities from 0.9 to 21.6 J/cm² across fractions. That wide range reflects heterogeneous research; it is not a home-use protocol.

The reviewed literature also describes a non-linear, bell-shaped dose response. In plain terms, more power, more time, or closer placement is not automatically better. Excessive energy density may be inhibitory in some research settings.

When comparing devices, look past "red," "NIR," or "dual wavelength" labels. Check whether the manufacturer provides verified information about:

1. Wavelengths emitted
2. Irradiance at a stated distance
3. Treatment area and coverage
4. Recommended positioning and exposure instructions
5. Safety directions, including eye guidance and heat-related precautions

Without those details, it is difficult to compare the dose a device may deliver at the skin surface---let alone at depth.

Deep and high-stakes claims need a higher evidence bar

Claims involving the brain, bone, internal organs, a particular deep joint, or a neurological condition should be evaluated especially cautiously.

The evidence summarized here does not provide direct, controlled human evidence that a consumer red or NIR device delivers a clinically meaningful dose to bone, internal organs, a specific joint, or a brain target. That is an evidence gap, not proof that delivery or effects never occur. But it means broad "deep penetration" language should not be treated as confirmation of a treatment effect.

Neurological research makes the same point. Much of the reviewed evidence in neurology, psychiatry, and ophthalmology was preclinical, with limited human evidence from small pilot studies and case reports. In one reported 660-participant stroke trial, transcranial photobiomodulation did not significantly differ from sham treatment, despite favorable trends in some less-severe subgroups. That result applies to a particular protocol; it does not settle every NIR question. It does show why promising mechanisms and theoretical penetration are not enough.

Safety checkpoint: Follow the device's instructions for eye protection, positioning, and exposure. Review safety information carefully if you have impaired sensation, use photosensitizing medicines, are pregnant, are receiving active cancer treatment, or are considering use near the thyroid area. For a diagnosed condition or a high-stakes target, discuss the plan with an appropriate clinician rather than relying on a consumer-device claim.

A practical way to evaluate red, NIR, or both

Before choosing a device or routine, use this sequence:

1. Define the target. Is it primarily superficial, or is it beneath multiple layers of tissue?
2. Look for evidence for the exact goal. Do not infer a clinical outcome from a wavelength's theoretical penetration.
3. Compare verified specifications. Check wavelengths, irradiance, treatment area, distance, timing instructions, and safety information.
4. Review the risk context. A red-plus-NIR label alone does not establish the right treatment, dose, or outcome.

If you are evaluating a BestQool device, use its specification and safety resources to verify those practical details. Start with the target and the evidence---not with the assumption that red is "for skin" and NIR is "for deep tissue."